Video summary

PATOLOGÍA NEUROMUSCULAR

Main summary

Key takeaways

Educational

Main ideas / concepts covered

1) What “neuromuscular pathology” evaluation should include

Core clinical domains to assess

  • Motor function
  • Sensory function
  • Osteotendinous (myotatic) reflexes
  • Autonomic function

Motor exam framing

  • Negative motor symptoms (impairment such as):
    • Weakness
    • Segmental paresis/atrophy
    • Fatigability
      • Fatigability (declining performance with exercise) is noted especially in motor endplate diseases.
  • Positive motor signs/symptoms:
    • Fasciculations (often seen in motor neuron disease; not discussed further here)
    • Cramps
    • Myalgias (muscle pain; distinguish from joint disease)
    • Muscle rigidity / (anti-)spontaneous rigidity
  • Muscle breakdown concept
    • Myoglobinuria (“dark brown urine”) as a sign of significant muscle damage.
  • Muscle replacement concept
    • “Schubert’s trophy” / focal atrophy
      • Not true muscle hypertrophy
      • Reflects fatty replacement
      • Seen mainly in certain muscular dystrophies

Strength assessment

  • Strength grading via the MRC scale (0–5).
  • Group motor findings by body regions (e.g., facial/ocular/other, trunk, proximal limb sectors), typically displayed in a table.

2) Sensory evaluation priorities for neuropathies

  • Determine whether sensory loss involves:
    • Large-fiber vs small-fiber modalities
  • Key teaching point:
    • Not all neuropathies include neuropathic pain.
  • If neuropathic pain is present, typical positive sensory phenomena:
    • Follows a nerve root/plexus distribution
    • Can be burning, sharp, cold, or pressure-like
    • Usually well-defined and tracks the affected territory
  • Determine whether sensory symptoms are:
    • Central distribution or peripheral/nerve distribution

3) Reflex evaluation and topographic-pattern thinking

  • Myotatic reflexes must be mapped segmentally to categorize neuropathy type.
  • Reflex pattern attributes to document:
    • Proximal vs distal deficit
    • Symmetry vs asymmetry
    • Predominant fiber type:
      • Thin fibers (sensory perception) vs thick fibers (fine/positional sensation)
    • Temporal profile: acute / subacute / chronic
    • Motor-response pattern: whether atrophy and reflex loss predominate vs are relatively minimized
  • Always ask for remote history that may explain cause:
    • Toxic exposure (drugs)
    • Hereditary history
    • Other relevant medical history (implied)

Neuropathy classification and expected clinical patterns

4) Two main groups for neuropathies

  • Symmetrical neuropathies
  • Asymmetrical (active) neuropathies
    • Further subdivisions include:
      • Focal or distal autonomic neuropathies
      • Multifocal neuropathies
        • Involve more than one limb/nerve
        • Often asymmetrical and not all at the same time

5) Distal symmetrical polyneuropathy (“length-dependent” pattern)

  • Common internal-medicine neuropathy:
    • Sensory and motor impairment of distal reflexes
  • Often length-dependent:
    • Begins distally (e.g., toes)
    • Ascends over time:
      • to ankles/legs/knees → then hands
  • Motor weakness/atrophy:
    • Starts in intrinsic foot muscles → ascends → hands
    • Motor component often appears more clearly via electrophysiology
  • Reflex progression concept (example logic):
    • Early distal lower-extremity neuropathy may reduce Achilles reflexes while patellar reflexes remain
    • With progression, both may reduce while more proximal reflexes remain until later
  • Autonomic involvement may accompany:
    • Sweating changes
    • Skin color changes / trophic changes (implied dryness/redness)

6) Characteristic hereditary/polyneuropathy signs

  • Pes cavus pattern:
    • Shortened Achilles tendon
    • Prominent cavus arch
    • Retraction related to extensor tendons (described as extensor digitorum longus retraction)
    • Leads to abnormal gait with load at metatarsal heads
  • Imaging/visual example concepts:
    • Uneven compartment muscle atrophy in distal legs

Guillain-Barré syndrome (GBS): differential diagnosis and management

7) Why GBS is highlighted

  • Described as the archetypal diagnosis in the acute weakness differential.
  • Immune-mediated mechanism (high-level):
    • Autoimmune attack related to molecular similarity between infectious targets and peripheral nerve/Schnwann-related structures.
  • Typical clinical course:
    • Ascending weakness over days to weeks (a few days up to ~1 month)
    • Typically motor-predominant
      • Paresthesias/pain can occur, but sensory deficits are less prominent than motor weakness
    • Trunk dysfunction and respiratory insufficiency can develop

8) Expected severity timeline (key numbers mentioned)

  • Maximum deficit reached:
    • 50% by 2 weeks
    • 80% by 3 weeks
    • ~90% by 4 weeks
  • Course:
    • Generally monophasic (peak then usually no continuous worsening)
    • Relapses can occur

9) Triggers / associated antecedents

  • Recent respiratory viral infection
  • Diarrheal illness
  • Vaccinations
  • Surgery
  • Pregnancy

10) Prognosis / critical complications (figures mentioned)

  • A spectrum from relatively benign to emergency:
    • Some patients walk despite tetraparesis with major lower-extremity weakness
    • Others require ventilatory support/internal-complication care
  • Autonomic complications noted:
    • Bradycardia/tachycardia
    • Hypotension/hypertension
    • Cardiac output / “cardiac appearance” changes (as stated)
  • Mortality:
    • ~5%, from acute respiratory failure, autonomic/cardiovascular causes, or sepsis complications

11) Diagnostic pillars for GBS

  1. Exclusion diagnosis
    • Confirm GBS primarily by ruling out other causes of acute weakness
  2. Lumbar puncture (CSF) study
    • Hyperproteinemia with normal mononuclear cell count
    • CSF cells expected ≤ 5 (as stated)
    • Protein elevation may begin end of week 1 and increases with evolution
  3. Electrophysiology
    • EMG/nerve conduction abnormalities may appear around end of week 1 or during week 2
    • Not an absolute requirement to delay initial treatment

12) Variants mentioned (taxonomy-level)

  • Clinical variants:
    • Miller type variant (described as benign)
    • Guillain variant with pharyngeal–brachial involvement
    • “Militant” type (noted as debated with other names)
    • Zonal variants:
      • can be purely motor or sensory-motor
  • (Not deeply detailed here; included as a classification framework.)

13) Treatment approach (stepwise methodology)

General principles

  • GBS is a medical emergency.
  • Practical workflow (intern responsibilities):
    • Make the diagnosis
    • Exclude other causes of acute weakness
    • Communicate immediately with the care unit (at least intermediate care initially)
  • Prioritize:
    • Respiratory function
    • Autonomic function

Respiratory monitoring details

Monitor for:

  • Dyspnea
  • Tachycardia
  • Need for accessory muscles
  • Sternocleidomastoid and other muscle use
  • Assess diaphragm dysfunction:
    • Dysfunction mapped to C2–C4 regions (as stated)
  • Check cough effectiveness (ability to take breath)
  • Blood pressure changes considered late in respiratory failure

Numerical spirometry concept (as taught):

  • Ask the patient to count breaths aloud on exhalation.
  • Typical normal ~40 (higher if non-smoker per statement).
  • ~20 or less suggests severely reduced forced vital capacity → prepare for ventilatory support.

Disease-modifying treatments

Two options:

  • Plasmapheresis
    • Remove ~50 mL/kg per session
    • Perform with an interval (“one between”) to reduce hypotension
    • Coagulation monitoring referenced (number “five” mentioned but unclear)
  • IV immunoglobulin
    • 2 g/kg over 5 days

Timing rule:

  • Must be done before 2 weeks of evolution for maximum effectiveness.

Outcomes:

  • Both therapies produce similar outcomes
  • Benefits described:
    • Fewer ICU days
    • Fewer days on mechanical ventilation
    • Better functional prognosis

Corticosteroids

  • Not used; described as worse outcomes vs placebo.

Escalation

  • Ventilation/support for respiratory decline.

Differential diagnosis: what must be ruled out

Acute spinal cord causes:

  • Myelitis
  • Decompensated tumors compressing spinal cord (dorsal/cervical)
  • Vasculitis-related myelitis/lesions

Acute neuropathy/metabolic/toxic causes and other disorders:

  • Acute intermittent forms (mentioned)
  • Motor plate diseases (later myasthenia gravis context referenced)
  • Hereditary metabolic muscular disease mentions
  • Poisonings:
    • Organophosphates
    • Environmental/occupational toxins
    • Botulinum toxin exposure
    • Marine toxins
  • Some toxin-related weakness can evolve within hours.

Radicular syndromes, cranial neuropathies, and entrapment neuropathies (overview)

14) Radicular syndromes

  • Described as a group of focal symmetric neuropathies
  • Radicular pain patterns by level (examples):
    • Cervical → sciatica-like radiating pain; “cervical root” patterns
    • High lumbar (L2–L4) → lumbago-type symptoms
    • L5/S1 → lumbosacral radicular syndromes
    • Thoracic → pain radiating along the costal arch; may involve abdominal wall muscles (motor involvement)

Etiologic framework:

  • Degenerative/toxic-degenerative processes affecting intervertebral discs/vertebral bodies:
    • Direct compression or adjacent inflammation
  • Trauma
  • Tumors compressing/infiltrating spinal cord
  • Infectious causes (e.g., shingles)
  • Inflammatory causes

Initial treatment approach:

  • May be managed by a general practitioner if classic pain presentation:
    • Pain control with paracetamol
    • Relative rest (few days)
    • Consider muscle relaxants
    • Physiotherapy
    • If pain not debilitating: expect ~2 weeks
  • If severe/unmanageable pain or motor impairment appears:
    • Investigate etiology
    • Imaging: dynamic MRI for stenosis when indicated
    • Urgent referral if:
      • severe unmanageable pain despite measures
      • early motor deficits
      • cauda equina / “worse scenario” with sphincter impairment (described as “sindrome with… impairment of 3s”)

Referral urgency:

  • Neurologist, spine traumatologist, or neurosurgeon depending on scenario.

15) Cranial neuropathies overview: Bell’s palsy (idiopathic facial palsy)

Features:

  • Inflammation of the facial nerve
  • Acute peripheral facial pain developing within 24–72 hours
  • Associated:
    • tongue pain
    • tearing
  • Worsens with facial musculature involvement

Key differentiation:

  • Peripheral facial nerve involvement differs from central causes:
    • central: frontal/auricular branches affected with “entire half of face” involvement

Differential considerations:

  • Systemic malignancy-related causes
  • Skull base infections
  • Other cranial nerve involvement
  • Otitis / laryngitis / tumors
  • Ramsay Hunt syndrome
    • herpes zoster with rash on tragus (without external auditory canal involvement mentioned)

16) Outcomes and treatment for Bell’s palsy

Idiopathic course:

  • ~85% recover within 4–6 weeks
  • ~15% poorer outcomes:
    • about one-third of that group may have severe residual facial paralysis

Escalation indicators:

  • No recovery within 3 months
  • Progressive worsening over weeks/months (not acute)

Treatment approach:

  • Eye protection (mask/care, especially at night)
  • Artificial tears
  • Prednisone regimen (as stated):
    • start around 12 mg/kg for 1–5 days
    • then gradual taper down to 10 (units unclear due to subtitle noise)
  • Antiviral (acyclovir/valacyclovir):
    • described as debatable/controversial
  • Note:
    • Telephone/ice pack/other tests are mentioned elsewhere in the notes but in myasthenia gravis context (not here).

17) Other mononeuropathies mentioned

  • Third cranial nerve palsy
    • painful ophthalmoplegia; “rule out compressive pathology” emphasized
  • Carpal tunnel syndrome
    • nocturnal paresthesias starting in first 3–4 fingers
    • worsens with wrist flexion/extension and repetitive hand work
    • possible thenar/eminence atrophy → impaired thumb opposition/grip
    • confirmation via physiologic stress tests or ultrasound (as stated)
  • Ulnar neuropathy
    • symptoms in 4th/5th digits
    • progressive intrinsic hand muscle atrophy
    • possible elbow entrapment contribution if no other cause
  • Radial nerve compression (“Saturday night” style)
    • wrist/finger extensors weakness → “drop/wrist” pendulous hand
    • recovery often good over weeks to 1–1.5 months
  • Common peroneal/fibular nerve compression
    • foot dorsiflexion weakness after compressive insults (including tight casts/trauma)
  • Multifocal mononeuritis
    • asynchronous, asymmetric involvement across at least two nerves/limbs
    • associated with systemic vasculitis (as described)

Polyneuropathy classification and causes

18) Classification by timing and electrophysiology

  • Timing:
    • acute, subacute, chronic
  • Electrophysiologic perspective:
    • categories referenced (garbled subtitles suggest acquired vs hereditary and demyelinating vs axonal-like variants)
  • Causes grouped broadly:
    • Acquired: physical, metabolic, toxic, deficiency, infectious, immune-mediated
    • Hereditary: genetic causes
  • Referral concept:
    • severe acute deterioration with unclear etiology → urgent evaluation
    • neuropathy workup involves electrophysiology/topographic/fiber-type screening

19) Diabetic polyneuropathy patterns and course

Most frequent in diabetics:

  • distal symmetric sensory polyneuropathy
  • distal symmetric sensorimotor polyneuropathy

Pain:

  • up to ~1/3 report pain (per statement)
  • most have sensory signs without pain

Course:

  • typically progressive over years
  • can improve with metabolic control
  • autonomic involvement can occur

Diabetic trunk radiculopathy:

  • less frequent (~1% stated)
  • lumbar pain radiating to thigh:
    • initially one-sided, then bilateral after weeks/months
  • gluteus medius atrophy described
  • recovery may take months to >1 year, sometimes with residual sequelae

20) Diabetic neuropathy management (methodology)

  • First principle:
    • optimize metabolic control (especially Type 1 > Type 2)
  • Lifestyle recommendations:
    • low-fat balanced diet
    • aerobic exercise >150 minutes/week
  • Manage comorbidities:
    • hypertension
    • dyslipidemia
    • avoid smoking

Pain management:

  • only for patients with painful sensory impairment
  • not routinely treated if only sensory deficits
  • neuropathic pain management by specialists

Drug categories mentioned:

  • antidepressants
  • anticonvulsants
  • opioids
  • choice depends on adverse-effect profile

“First-line/second-line” medication concepts:

  • garbled subtitles mention items that appear mis-transcribed (e.g., one called “oxytocin” and “Mini-Tri”)
  • sedation noted as a drawback for one option
  • ice water described for nocturnal sensitive pain

Myopathies: definition, syndromic patterns, and key investigations

21) Definition of myopathy

  • Myopathy = structural and/or functional alteration of muscle:
    • structural protein alterations
    • membrane/contractile system dysfunction
    • ion channel dysfunction
    • energy/ATP generation failure
    • can be secondary to immunologic mechanisms

22) Typical clinical “myopathic syndrome” pattern

  • Most typical taught pattern:
    • proximal tetraparesis predominating in:
      • waist/proximal trunk
      • shoulder girdle
    • sensory involvement:
      • limited to muscle (not true nerve sensory loss)
  • Reflexes:
    • normal or diminished, depending on severity
  • Pain:
    • may include myalgias, exercise-induced myalgia, cramps
  • Course:
    • variable: subacute to chronic
  • Possible systemic involvement:
    • especially cardiac rhythm involvement noted as important

23) Hereditary myopathy “topographic syndromes” (examples)

  • Distal-muscle preferential involvement:
    • pseudo–polyneuritis motor pattern
  • Scapulohumeral pattern:
    • face/periscapular region/middle arm involvement (with/without peroneal involvement)
  • Facial/eye-related preferences and other named syndromic patterns are referenced, including:
    • episodes with functional (episodic) predominance rather than fixed atrophy

24) Core investigations for suspected myopathy (method)

  • (Section begins in the source text but is incomplete in the provided notes.)

Original video